HC Wainwright & Co. Initiates Coverage On Terns Pharma with Neutral Rating, Announces Price Target of $6
HC Wainwright & Co. analyst Ed Arce initiates coverage on Terns Pharma (NASDAQ:TERN) with a Neutral rating and announces Price Target of $6.